RESULTS: Rivaroxaban resulted in a hypocoagulant
state that remained largely unaltered upon subsequent 50% dilution with S/D-treated plasma or FFP. Using S/Dtreated plasma as a diluent, clot stability decreased due to its low α 2 -antiplasmin. Dilution with saline and albumin induced a profibrinolytic state and further deteriorated the impaired hemostatic potential of rivaroxabananticoagulated blood, even after PCC and fibrinogen support. Combined use of plasma (either FFP or S/D treated) and PCC, however, considerably improved both coagulation and clot stability.
CONCLUSION:
In the setting of rivaroxaban anticoagulation and major blood loss, transfusing plasma together with PCC may provide the most effective resuscitation approach with the notion that additional antifibrinolytic drug support (e.g., tranexamic acid) is likely required. U ncontrollable hemorrhage is the leading cause of death in traumatically injured patients. 1 Hampered coagulation together with hyperfibrinolysis is a condition that may play a major role in this life-threatening coagulopathy. [2] [3] [4] In an attempt to secure intravascular volume and tissue oxygenation, crystalloid fluids and red blood cells (RBCs) are frequently transfused as the first-line treatment of severe hemorrhagic shock. 5, 6 A strategy to avoid coagulopathy includes the administration of fibrinogen concentrate, the antifibrinolytic drug tranexamic acid (TXA), platelets, and plasma. 7, 8 For resuscitation with plasma, single donor fresh frozen plasma (FFP) or solvent/detergent (S/D)-treated plasma is used, the latter consisting of a blood group-specific pool of over 600 single-donor units (treated with tri-n-butyl phosphate and 1% Triton X-100). Major advantages of S/D-treated plasma over FFP are the between-batch homogeneity and the reduced risk of pathogen transmission and its safety with respect to transfusion-related acute lung injury and lower likelihood of allergic reactions. 9 Disadvantages of S/D-treated plasma may be the low level of α 2 -antiplasmin and the concomitant hyperfibrinolytic phenotype, which may be counteracted by its enhanced coagulation activity due to loss of protein S function. 10 Prothrombin complex concentrate (PCC), a mixture of partly purified human plasma vitamin K-dependent coagulation factors (FII, VII, IX, X, and protein C and S) can be considered in combination with or as an alternative to plasma.
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The direct factor Xa inhibitor (FXa-I) rivaroxaban, among others, is used for stroke prevention with atrial fibrillation, as well as thromboprophylaxis in patients undergoing orthopedic surgery and treatment of venous thromboembolism. [14] [15] [16] For bleeding management in patients taking rivaroxaban, first, drug intake is discontinued. In cases of severe bleeds, for example during trauma, drug cessation is not sufficient, and reversal agents must be used. 17 A specific reversal agent, andexanet alfa, recently passed phase III trials 18 and got Food and Drug Administration approval. PCC, for decades proven to be effective in reversing anticoagulation by vitamin K antagonists, has not only shown rapid normalization of the laboratory variables prothrombin time and endogenous thrombin potential in healthy volunteers taking rivaroxaban, 19, 20 but PCC also corrected hemorrhage in animal bleeding models and recently in humans. [21] [22] [23] [24] The use of rivaroxaban or other FXa-I may add to the development of trauma-or surgery-induced coagulopathy. Otherwise, simultaneous fluid replacement with albumin, salt solutions, or plasma may not only affect the coagulation profile due to a lower hematocrit, platelet count, and dilution of coagulation and fibrinolytic proteins (especially with sodium chloride [NaCl] and albumin), but also lowers rivaroxaban levels in plasma.
We employed an in vitro coagulopathy model with combined hyperfibrinolysis and rivaroxaban anticoagulation and studied different resuscitation approaches, including the use of 0.9% NaCl, fibrinogen, PCC, S/D-treated plasma, TXA, and their combinations. We also tested the effects of these regimens in diluted plasma from orthopedic patients taking their first dose of rivaroxaban 16 to 28 hours after surgery.
MATERIALS AND METHODS

Blood collection and plasma preparation
Blood samples were collected from apparently healthy volunteer donors after informed consent by standard venipuncture using a 21-gauge needle and 10-mL vacuum collection tubes containing trisodium citrate (109 mM). For each set of experiments, at least six normal subjects were included. For thromboelastography (TEG) analysis, samples were kept at room temperature and used within 5 hours after blood collection. Plasma was prepared by centrifugation of citrated whole blood for 10 minutes at 2000 × g within 2 hours after venipuncture. Platelet-poor plasma was collected, aliquoted, snap-frozen in liquid nitrogen, and stored at −20 C or below until further use.
In vitro anticoagulation was achieved with rivaroxaban (Bayer Healthcare) at a plasma concentration of 50 ng/mL (trough value) and 300 ng/mL (peak value) by spiking 3-μL rivaroxaban dilutions in dimethyl sulfoxide (DMSO) to 1 mL of plasma (for whole blood assuming a hematocrit of 40%). Nonanticoagulated samples contained an equal amount of the DMSO solvent. Alternatively, plasma was prepared from citrated whole blood collected from orthopedic patients (n = 6) who underwent total hip arthroplasty in Finland and taking their first dose of rivaroxaban. Written informed consent was obtained prior to blood withdrawal. The ethical permit from the Oulu University Hospital in Finland (12/2011, amendment 9/2016) mandated a nationwide study. The sample was taken at 3 hours after the first rivaroxaban oral dose to obtain peak levels, at 16 to 28 hours after the surgery. Due to the long distance between the location of patient sampling and our TEG facility, whole blood samples for TEG assays were not obtained. Platelet-poor plasma was prepared, frozen, and stored until analysis. Rivaroxaban concentration was analyzed with a rivaroxaban-calibrated anti-Xa assay with an automatic hemostasis analyzer (ACL Top 500, Instrumentation Laboratory).
Resuscitation fluids, coagulation factor concentrates, and inhibitors
Normal pooled plasma was prepared from 32 FFP units (Sanquin). S/D-treated plasma (blood group A) was from Octapharma AG. PCC (Cofact) and 5% albumin solution (Albuman) were from Sanquin. Saline (0.9% NaCl) was from Fresenius Kabi. Fibrinogen (Haemocomplettan P) and TXA (laboratory grade) were purchased from CLS Behring and Sigma-Aldrich, respectively. Potato carboxypeptidase inhibitor was from Sigma Aldrich. α 2 -Antiplasmin was obtained from Mybiosource.
In vitro coagulation models
We employed two model systems for hyperfibrinolysis: viscoelastic measurement in whole blood (TEG) and a cell-free fibrin generation clot lysis test (FGCLT) in platelet-poor plasma with optical detection of fibrin formation and clot lysis. In both models, coagulation was triggered by tissue factor (TF) and fibrinolysis by tissue plasminogen activator (tPA). Thrombin generation assay (calibrated automated thrombography [CAT] ) in the absence of tPA was employed as a dedicated test solely to investigate the effect of resuscitation on the anticoagulant effect of rivaroxaban. Resuscitation interventions were mimicked by diluting donor plasma with saline, FFP, or S/D-treated plasma, by adding clotting factor concentrates (fibrinogen, PCC), and by adding TXA.
We chose plasma 1:1 dilutions, as a large proportion of patient plasma is likely to be replaced with resuscitation fluids during treatment of major bleeding. 8 PCC was added to approximate the recommended dosing of 50 IU/kg body weight for rivaroxaban reversal. 19, 20 Fibrinogen dosing was chosen to restore its normal level. TXA level applied was set at 2.5 μg/mL to allow clot lysis time (CLT) calculations within our experimental time frame, which was in the same order of magnitude as observed in plasma from patients after therapeutic TXA administration (5-15 μg/mL).
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Whole blood TEG (Haemonetics) was performed with minimally altered citrate-anticoagulated whole blood (containing rivaroxaban or DMSO) and samples thereof diluted with plasma, saline, or albumin solution. To avoid unwanted RBC agglutination during TEG analysis upon whole blood dilution with pooled plasma, blood from blood group O donors was used for experimentation only. The added volume of resuscitation fluid was equal to the volume of plasma in the original whole blood sample, assuming a hematocrit of 40% (the range of hematocrit in the citrated whole blood samples was 36%-45%). Other reagents and supplements were added just before the start of the TEG measurements, including TF (Innovin, Siemens Healthcare Diagnostics), tPA (Actilyse, Boehringer Ingelheim Gmbh), and when indicated TXA, fibrinogen, α 2 -antiplasmin, and PCC. All reagents and supplements were diluted in Trisbuffered saline (10 mM Tris, 150 mM NaCl, pH 7.4), and their addition inevitably further diluted the blood sample. We confined this extra dilution to a minimum and confirmed in all samples that the volume of added reagents and supplements accounted for 14% v/v of the total extracellular volume. Final concentration of TF, tPA, and TXA were, respectively, 1 pM, 200 ng/mL, and 2.5 μg/mL. PCC was added to equal a concentration in undiluted plasma of 2 IU/mL. Fibrinogen and α 2 -antiplasmin (2 mg/mL and 1 U/mL, respectively) were added to the saline compartment to restore their normal levels. S/D-treated plasma was supplemented with 0.6 IU/mL α 2 -antiplasmin to restore its value to 1 IU/mL. Finally, 340 μL of the prepared sample was pipetted into a TEG cup, and measurement was started after adding 20 μL 0.2 M calcium chloride (CaCl 2 ).
The cell-free FGCLT was performed as described by Bakhtiari and colleagues. 25 In this assay, the final plasma concentration was 50% v/v. The remaining 50% v/v was Tris-buffered saline, containing additives (PCC or carboxypeptidase inhibitor when indicated) and start reagents (TF, phospholipids, tPA, and CaCl 2 at final concentrations of 0.5 pM, 4 μM, 50 ng/mL, and 15 mM, respectively). This assay measures turbidity (405 nm) of clotting plasma in time. The first part of the optical density tracing from zero to maximum turbidity characterizes clot formation, with clotting time (CT) defined as the time from start of the measurement to half maximal turbidity (midpoint of the clear to maximum turbid transition). The second part of the tracing with declining optical density represents clot lysis. CLT was defined as the time between clotting time and half maximal lysis (midpoint of the maximum turbid to clear transition). Plasma samples were subjected to FGCLT either directly or after dilution with an equal amount of pooled FFP or S/Dtreated plasma. CAT reagents were obtained from ThrombinoscopeStago. CAT was performed with donor plasma directly and after 50% dilution with either S/D-treated plasma or pooled FFP. As per manufacturer's instruction, the CAT assay should be performed at a 66.7% v/v final plasma concentration (80 μL plasma, 20 μL reagents containing TF and phospholipids, or 20 μL calibrator, 20 μL start reagents containing CaCl 2 and the thrombin substrate). To be able to add supplements like PCC, we lowered the final plasma concentration to 50%, compatible with our FGCLT and as reported previously. 26 TF concentration was 1 or 5 pM.
Statistical analysis
Computer software (GraphPad Prism 7 package, GraphPad Software, Inc.) was used for statistical calculations. Spiking experiments with pooled normal plasma were performed on three separate occasions and were assumed to follow a normal distribution. For experiments with individual whole blood and plasma samples, the Shapiro-Wilk normality test was used. For pairwise comparisons, the parametric paired t test or the nonparametric Wilcoxon matched pairs signedrank test was used when appropriate. Differences were considered significant at a p value less than 0.05.
RESULTS
Reduction of rivaroxaban concentration by plasma dilution; influence on cell-free coagulation and fibrinolysis
The thrombin generation assay is an accepted evaluation method for anticoagulation by direct oral anticoagulants, including the frequently used FXa-I rivaroxaban. We employed the CAT approach with rivaroxaban-anticoagulated plasma and used CAT-peak to investigate the fluid replacementinduced rivaroxaban dilution. To capture differences in rivaroxaban sensitivity in various types of plasma, we first compared titrations of rivaroxaban in pooled FFP with that in S/D-treated plasma. At 1 pM TF (Fig. 1A , left panel), residual CAT-peak in FFP and the more procoagulant S/D-treated plasma differed clearly. At 200 ng/mL rivaroxaban, for example, thrombin generation in FFP was negligible, while it was still significant in S/D-treated plasma. Differences between the plasmas were less pronounced, at 5 pM, than at 1 pM of TF (Fig. 1A , right panel). We next performed dilution experiments with plasma collected from rivaroxaban-treated patients (a single dose of 10 mg). The peak 3-hour levels of rivaroxaban in Patients' 1 through 6 undiluted plasma were 71, 98, 13, 161, 81, and 99 ng/mL, respectively. The response to 1 pM TF of undiluted sample in CAT was below the lowest 2.5 percentile of 40 normal plasmas for three of six patients only, and did not improve upon 50% dilution with FFP, but for five of six patients the CAT response was partially corrected by dilution with S/Dtreated plasma ( CAT-peak is a highly sensitive variable both to rivaroxaban and to differences in procoagulant behavior between FFP and S/D-treated plasma but does not directly reflect fibrin clot formation and stability. The influence of fluid replacement on clot formation and stability in rivaroxabananticoagulated plasma is shown in Fig. 2 . These experiments were performed at a low TF concentration (0.5 pM), enabling accurate and sensitive clotting time determination of this nonautomated test. To monitor clot stability, we included tPA. Clotting times of all undiluted plasmas derived from rivaroxaban-treated patients, except Patient 3 with the lowest rivaroxaban level, were all more prolonged than the values in 15 normal plasma samples, clearly indicating anticoagulation ( Fig. 2A, top panels) . These prolonged clotting times only marginally improved upon 50% dilution of rivaroxaban-anticoagulated patient plasma using either pooled FFP-or S/D-treated plasma. On the other hand, CLT of rivaroxaban-anticoagulated plasma was in the normal range for most patients but shortened upon dilution, especially in S/D-treated plasma ( Fig. 2A , bottom panels). The influence of dilution at high concentrations of rivaroxaban was examined by using FFP spiked with rivaroxaban up to 500 ng/mL (Fig. 2B) . Dilution of rivaroxabanspiked FFP with either pooled FFP-or S/D-treated plasma clearly improved the clotting times (Fig. 2B, top panel) , while correction of the CLT, albeit only partial at rivaroxaban levels greater than 100 ng/mL, was observed for the pooled FFP but not for S/D-treated plasma (Fig. 2B , bottom panel).
Hemostatic profile of rivaroxaban-anticoagulated whole blood-comparison between dilution with saline, albumin, FFP, and S/D-treated plasma
The drawbacks of the CAT assay and the FGCLT are the sample dilution with reagents (50% v/v in our setup) and the absence of blood cells and platelets. We therefore performed TEG experiments with citrated whole blood where reagents accounted for only 14% of the total extracellular volume. For logistic reasons, these experiments were performed with whole blood samples of healthy volunteers that were spiked in vitro with rivaroxaban. Plasma compartment of the native and rivaroxaban-anticoagulated whole blood samples was diluted two-fold, with the resuscitation fluid assuming a hematocrit of 40% (Fig. 3) . Representative TEG tracings are shown in Fig. 3A . Dilution of native, citrated whole blood with pooled FFP had virtually no effect, whereas dilution with S/D-treated plasma resulted in a marked shortening of the CLT (Fig. 3B) . A 50% dilution of the plasma compartment of native samples with the saline or albumin solution profoundly impaired the TEG tracing, characterized primarily by reduced maximal amplitude (MA) and shortened CLT (Fig. 3) . Main impact of spiking native citrated whole blood with rivaroxaban was on the reaction time R (1.8-fold prolongation; p < 0.005). Influence on R-time of the subsequent 50% dilution (plasma compartment) of rivaroxaban-anticoagulated blood with resuscitation liquid was only marginal, showing some improvement by NaCl and albumin. Other TEG parameters did not improve, except for a minor correction of the α angle when diluted with pooled FFP-or S/D-treated plasma. In fact, dilution by fluid in general led to a further deterioration of the hemostatic profile of rivaroxaban-anticoagulated blood that is mainly due to reducing clot stability. Blood dilution with pooled FFP had the least negative effect on TEG tracings in both the absence and presence of rivaroxaban.
Role of fibrinolytic inhibitors in fluid replacement under rivaroxaban
We investigated whether fibrinolysis inhibitors may improve clot stability under rivaroxaban when using saline-or S/D-treated plasma for resuscitation. The antifibrinolytic drug TXA abrogated clot lysis not only in rivaroxabananticoagulated whole blood diluted with saline, but also when diluting with S/D-treated plasma (Table 1) . Dilution with saline-or S/D-treated plasma, decreases, among others, the natural fibrinolysis inhibitor α 2 -antiplasmin. Restoring α 2 -antiplasmin corrected the CLT to correspond to minimally diluted whole blood ( Table 1 ). The fibrinolytic inhibitors TXA and α 2 -antiplasmin, as expected, did not affect TEG R-time. On the other hand, both fibrinolytic inhibitors improved MA to some extent, probably due to delayed fibrinolysis (Table 1) . To negate the effect on clot stability, most resuscitation fluids thus may require additional support of antifibrinolytic drugs.
Procoagulant drug support in fluid replacement under rivaroxaban
The low MA in our TEG analysis of saline-diluted blood (see Fig. 3 ) can be interpreted as a shortage of fibrinogen. Therefore, fibrinogen was added to restore its level. This supplementation partially corrected MA and α angle, but did not influence TEG-R and CLT (Fig. 4) . We next argued that PCCs may be useful not only to correct for rivaroxaban anticoagulation but also to negate dilutional coagulopathy. As shown in Fig. 4 , addition of PCC had only a minor effect on TEG-R but significantly delayed clot lysis. Interestingly, combined use of PCC and FFP resuscitation strongly improved both TEG-R and CLT values (Fig. 5 ). This combined resuscitation approach seems more effective at the "trough" rather than at "peak" rivaroxaban levels, as indicated by the complete correction of TEG-R at 50 ng/mL rivaroxaban, whereas the correction was only partial at 300 ng/mL concentration of rivaroxaban. Combined use of S/D-treated plasma and PCC diminished the negative effect of S/D-treated plasma on CLT. Figure 6A shows an experiment mimicking an intervention with FFP and TXA followed by additional PCC support. While TXA only improved clot strength (MA) and stability (enhanced CLT), PCC partly corrected TEG-R while acting synergistically with TXA to improve clot stability (Fig. 6B) . The ability of PCC to delay clot lysis was analyzed in more detail using FGCLT. Figure 6C shows an example of the fibrin generation and clot lysis profile of the control and rivaroxaban-spiked normal plasma (50% final volume during measurement). Adding PCC to individual donor FFP (n = 8) spiked with rivaroxaban did not result in clotting time correction in this test. (Table 2 ). Clot stability, on the other hand, increased significantly (1.5-2-fold prolonged CLT). In our CAT assay, this corresponded to a significant improvement of the peak and overcorrection of endogenous thrombin potential, while lag time was only minimally affected ( Table 2 ). Prolongation of the CLT by PCC was abrogated in the presence of carboxypeptidase inhibitor, suggesting a role for thrombin activatable fibrinolysis inhibitor (Fig. 6C,D) .
DISCUSSION
In this study, the impact of different resuscitation fluids on hemostatic variables in rivaroxaban-anticoagulated plasma was explored, using both in vitro spiked samples and samples from hip arthroplasty patients taking rivaroxaban. Although rivaroxaban is diluted when transfusing resuscitation fluids, the anticoagulant effect is not nullified. We observed only a partial rivaroxaban concentration-dependent correction of the clotting time in vitro when applying FFP or S/D-treated plasma in a 1:1 ratio to endogenous, rivaroxabananticoagulated plasma. Furthermore, resuscitation fluids also dilute endogenous plasma components. This ultimately will result in a dilutional coagulopathy when using crystalloid fluids, further deteriorating coagulation that is already hampered by rivaroxaban. Ongoing rivaroxaban anticoagulation thus complicates the management of patients who experience acute major blood loss, suggesting the need for additional measures including the use of FXa-I-neutralizing drugs or hemostatic agents that bypass the anticoagulant. Hemostasis is determined not only by thrombin generation and subsequent fibrin clot formation but also by processes involved in clot dissolution. In both the absence and presence of rivaroxaban, we observed increased clot lysis when diluting with S/D-treated plasma. Clot lysis was further augmented when diluting with albumin or saline. It is known that manufacturing of S/D-treated plasma reduces the natural fibrinolysis inhibitor α 2 -antiplasmin levels to 40%, but concomitant enhanced clot lysis can be corrected by replacing α 2 -antiplasmin. 10, 27 Similarly, when we restored α 2 -antiplasmin or abrogated fibrinolysis by TXA, clot lysis in saline-diluted plasma was either normalized or strongly inhibited, respectively. To negate the disrupting effect on clot stability, most resuscitation fluids therefore may require additional but temporary support by antifibrinolytic drugs, as has been shown beneficial clinically in association with severe trauma.
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S/D-treated plasma is not only low in α 2 -antiplasmin but also has gained procoagulant properties during manufacturing ng/mL). * p < 0.05; ** p < 0.005, ns is not significant, compared with corresponding rivaroxaban-spiked blood (containing either 50 or 300 ng/mL rivaroxaban) without further mimicked intervention (Wilcoxon matched pairs test).
based methods, CAT and FGCLT, the required assay reagents and buffer further dilute the samples, resembling the salineinduced dilutional coagulopathy. In TEG, a much smaller dilution factor is used (14% in our setup). However, also in TEG at low TF, clot formation in rivaroxaban-anticoagulated plasma diluted with FFP-or S/D-treated plasma did not differ. Whether rivaroxaban-treated patients indeed benefit from S/D-treated plasma as a resuscitation fluid over FFP remains to be investigated. Blood dilution diminished fibrinogen concentration, as well as impaired clot strength and structure, which are associated with traumatic coagulopathy and massive bleeds. The poorest survival is evident among individuals having both decreased functional fibrinogen concentration and clot strength. 29, 30 Due to its diminished effects on thrombin formation, rivaroxaban anticoagulation compatibly associates with lower fibrin network density, that is, by formation of thick, loosely woven strands, instead of more resilient thin, tightly packed fibrin strands. [31] [32] [33] [34] [35] We found that adding fibrinogen indeed improves the TEG variable MA, in agreement with previous studies, suggesting fibrinogen as a limiting factor. 36, 37 The beneficial effect of fibrinogen added to saline-diluted whole blood anticoagulated with rivaroxaban, however, was marginal or absent for the TEG variables Rtime and CLT. Additional PCC support improved CLT but not MA and R-time. In contrast, PCC used in conjunction with FFP can correct for rivaroxaban anticoagulation, as indicated by improved R-time and MA. Yet correction to normal levels was achieved only at a low rivaroxaban level of 50 ng/mL, corresponding to typical trough concentrations. In a clinical cohort study, most patients experiencing major bleeding under rivaroxaban anticoagulation benefited from PCC. 24 Our data indicate that clinically induced dilutional coagulopathy by saline during rivaroxaban use cannot be fully corrected by PCC, illustrating the need for a specific rivaroxaban reversal agent. Andexanet alfa, recently approved by the Food and Drug Administration, is the targeted and promising alternative. The use of anticoagulation predisposes patients to a significant risk of surgery-or trauma-associated bleed. The most urgent treatment in life-threatening bleed is to secure intravascular volume. Unfortunately, the use of crystalloid resuscitation fluids easily leads to dilutional coagulopathy, impairing both coagulation and fibrinolysis. In our study we showed accelerated fibrinolysis by rivaroxaban. Hypocoagulability and hyperfibrinolysis are associated with multiorgan failure and mortality. 38, 39 A characteristic diamond pattern in TEG with rapid clot formation and subsequent fibrinolysis is the harbinger of death in patients with 100% mortality. 40 Countering volume loss with FFP combined with PCC resuscitation is probably most beneficial, as the increased thrombin generation produces stronger fibrin network and enhances thrombin activatable fibrinolysis inhibitor activation, thereby inhibiting fibrinolysis. An additional benefit with PCC is that volume overload and further dilution caused by excessive resuscitation liquid transfusions are prevented, while effectively increasing clotting factor availability. Moreover, PCC counteracted in our studies the minor reduction in clot stability by diluting blood with FFP that is likely the result of the simultaneous reduction in platelet count and platelet-released plasminogen activator inhibitor. 41 We observed that PCC synergize with TXA by enhancing clot stability. The effect of TXA on retarding clot lysis, however, is more prominent than that of PCC. On the other hand, the in vivo half-life of TXA (2-3 h) is shorter than that of coagulation factors in PCC (4-60 h). 42 TXA, inhibiting the proteolytic breakdown of the fibrin clot by plasmin, 7 will only be functional when enough clotting factors are present to form a clot. Therefore, early and combined administration of plasma, PCC and TXA seems most profitable but requires further clinical support on efficacy and safety. Major limitation is the in vitro nature of our study. Major blood loss-induced coagulopathy is not solely driven by the dilutional effect of fluid resuscitation. Severe tissue damage triggers a cascade of events leading to impaired platelet activity and endothelial dysfunction. 2, 4, 43 In our study, these effects of endothelium or platelets were not assessed. In addition, in traumatic coagulopathy, the TF component is enhanced. 2 In our in vitro experiments, we used TF concentrations ranging from 0.5 pM to 5 pM. It remains unclear whether these concentrations mimic local in vivo exposure to TF due to injury. Hyperfibrinolysis was anticipated by tPA addition. On the other hand, the patient plasma samples of our study originated from patients after orthopedic surgery, which may harbor some specific trauma features, including the proinflammatory postoperative state and mimicking of bone fractures. It is also noteworthy that, as these patients did not experience circulatory shock, the coagulation response is likely to differ from the traumatic coagulopathic state. Yet, in an effort to best capture the postinflammatory state after surgery, blood samples were obtained after patients had taken their first dose of rivaroxaban, while the patients were clinically stable at time of sampling. Another limitation is the lack of RBCs and platelet contribution in our in vitro explored interventions, as RBCs and platelets are usually transfused with plasma in a 1:1:1 fashion. 8 Yet the dilutional coagulopathy is primarily involved with artificial fluids, and administration of plasma and/or PCC resuscitation is crucial.
In conclusion, we do not recommend saline or albumin solution as the rescue therapy to achieve hemostasis in individuals on rivaroxaban anticoagulation. Our in vitro results suggest that the best resuscitation benefit while on rivaroxaban may be achieved with PCC in combination with FFP. S/D plasma use alone or in combination with PCC, albeit enhancing thrombin generation, may predispose patients to Individual donor citrated plasma (n = 8) was aliquoted and spiked with solvent (DMSO) or rivaroxaban to a final concentration of 50 and 300 ng/mL (0.3% v/v DMSO). Thrombin generation assay (CAT) and FGCLT were performed in the absence or presence of PCC (2 IU/mL plasma) at a final plasma concentration of 50% v/v. Data expressed as a percentage of control (without rivaroxaban and PCC) show a normal distribution (Shapiro-Wilk normality test) and are presented as mean AE SD. * p < 0.05; † p < 0.005; ‡ not significant compared with corresponding incubation without PCC (t test). CT = clotting time; ETP = endogenous thrombin potential.
increased fibrinolysis due to its diminished α 2 -antiplasmin concentration. Early supplementation with TXA, as recommended in general during major trauma, may benefit in these instances.
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